drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (biologic)
drug_description
An antibody–drug conjugate targeting HER2, consisting of trastuzumab linked to deruxtecan (a topoisomerase I inhibitor). It binds HER2 on tumor cells, is internalized, and releases a DNA-damaging payload with a bystander effect; it also inhibits HER2 signaling and can mediate ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
trastuzumab deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-HER2 monoclonal antibody (trastuzumab) linked to deruxtecan (DXd), a membrane-permeable topoisomerase I inhibitor. After HER2 binding and internalization, lysosomal cleavage releases DXd to cause DNA damage (topoisomerase I inhibition) with a bystander effect in neighboring cells. The antibody component also inhibits HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT06085755